Stock Movers ABB Soars, Legrand Rises, Novartis Down
Jul 17, 2025
ABB experienced a remarkable surge in stock value, driven by a 16% increase in order intake and strong demand for automation tools, showcasing a promising outlook amid global uncertainties. Meanwhile, Legrand's shares jumped to a record high after exceeding growth expectations, bolstered by robust sales in North America. In contrast, Novartis faced setbacks, with disappointing sales for its psoriasis drug and the impending retirement of its finance chief, leading to a notable decline in its stock performance.
AI Snips
Chapters
Transcript
Episode notes
ABB's Record Growth Surge
- ABB reported record order intake driven by strong demand for automation and electrical grid investments, especially in the US.
- AI boom fuels data center investments which boost ABB's electrification business, signaling a potential record year despite global uncertainties.
Legrand's AI-Driven Growth
- Legrand benefits from AI-related data center demand, raising its sales growth outlook.
- This offset weaker demand in other segments like European residential and US office markets.
Novartis Faces Mixed Signals
- Novartis raised guidance driven by strong cancer drug sales and initiated a major buyback.
- Disappointing psoriasis drug sales and CFO departure created headwinds, raising concerns about competition and future growth.